Nature Communications (Aug 2022)
CAF08 adjuvant enables single dose protection against respiratory syncytial virus infection in murine newborns
- Simon D. van Haren,
- Gabriel K. Pedersen,
- Azad Kumar,
- Tracy J. Ruckwardt,
- Syed Moin,
- Ian N. Moore,
- Mahnaz Minai,
- Mark Liu,
- Jensen Pak,
- Francesco Borriello,
- Simon Doss-Gollin,
- Elisabeth M. S. Beijnen,
- Saima Ahmed,
- Michaela Helmel,
- Peter Andersen,
- Barney S. Graham,
- Hanno Steen,
- Dennis Christensen,
- Ofer Levy
Affiliations
- Simon D. van Haren
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Gabriel K. Pedersen
- Center for Vaccine Research, Statens Serum Institut
- Azad Kumar
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Tracy J. Ruckwardt
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Syed Moin
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Ian N. Moore
- Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Mahnaz Minai
- Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Mark Liu
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Jensen Pak
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Francesco Borriello
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Simon Doss-Gollin
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Elisabeth M. S. Beijnen
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Saima Ahmed
- Department of Pathology, Boston Children’s Hospital and Harvard Medical School
- Michaela Helmel
- Department of Pathology, Boston Children’s Hospital and Harvard Medical School
- Peter Andersen
- Center for Vaccine Research, Statens Serum Institut
- Barney S. Graham
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Hanno Steen
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- Dennis Christensen
- Center for Vaccine Research, Statens Serum Institut
- Ofer Levy
- Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital
- DOI
- https://doi.org/10.1038/s41467-022-31709-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Respiratory syncytial virus is a major pathogen with burden observed and associated with childhood infection. Here the authors characterise a cationic adjuvant formulation and show single immunisation results in protection in a murine neonate model of respiratory syncytial virus infection.
